A randomized controlled clinical trial on etimicin, a new aminoglycoside antibiotic, versus netilmicin in the treatment of bacterial infections

Objective To compare the efficacy and safety of two aminoglycoside antibiot ics, etimicin and netilmicin, in the treatment of bacterial infections. Methods A randomized, open label, controlled clinical trial was conducted f or the treatment of 65 patients hospitalized with respiratory tract infecti ons, urinary tract infections, and skin and tissue infections. Thirty-four patients received etimicin and thirty-one patients received netilmicin at a dose of 100 mg every 12 hours by intravenous infusion. The duration of tre atment was 7-10 days in both groups. Results 47 patients were enrolled in the etimicin group; 35 patients were a ssessable for safety and 34 patients were assessable for efficacy, 46 patie nts were enrolled in the netilmicin group; 32 patients were assessable for safety and 31 patients were assessable for efficacy. The results show that overall efficacy was 85.3% for the etimicin group and 83.9% for the netilmi cin group, whereas bacterial clearance rates were 87.5% for the etimicin gr oup and 89.7% for the netilmicin group. The incidence of adverse reactions was 8.6% (3/35) and 9.4% (3/32), respectively. Conclusion Etimicin and netilmicin were effective and safe for the treatmen t of respiratory tract infection, urinary tract infection, and skin and tis sue infections. The results show there was no statistically significant dif ference between the two groups (P>0.05).